Moreover, AKT1, PPARG, SRC, EGFR, CASP3, ESR1, and the other potential core targets might be involved in the treatment of T2DM by modulating the following pathways, containing insulin resistance, hepatitis C, pancreatic cancer, insulin signaling pathway, TNF signaling pathway, and PI3K-AKT signaling pathway. This evidence concerns the gene AKT1 and familial pancreatic carcinoma.